

RESEARCH ARTICLE

Open Access



Thymus activity measured by T-cell receptor excision circles in patients with different severities of respiratory syncytial virus infection

Kiran Aftab Gul^{1,2,6*}, Tonje Sonerud^{3,4}, Hans O. Fjærli³, Britt Nakstad^{3,5}, Tore Gunnar Abrahamsen^{5,6} and Christopher S. Inchley^{3,5}

Abstract

Background: *Respiratory syncytial virus* (RSV) infection is an important cause of hospitalization in previously healthy infants. Immunological mechanisms predisposing infants to severe disease are poorly understood. Early biomarkers for disease severity may assist clinical decisions. We investigated T-cell receptor excision circles (TREC), episomal DNA made during thymic T-cell receptor rearrangement, and a marker for thymus activity, both during disease and in neonatal screening cards as a risk factor for RSV disease severity.

Methods: One hundred thirteen patients hospitalized with RSV infection <12 months of age, grouped by disease severity, were available for this investigation, in which we conducted both a prospective and a case-control study. The prospective study included 47 RSV positive infants (mild $n = 13$, moderate $n = 10$, severe $n = 24$). TREC counts were determined by PCR of DNA extracted from EDTA-blood collected on hospitalization, and corrected for lymphocytes using ANCOVA. The case-control study included 85 newborns who later in infancy became RSV positive (mild $n = 32$, moderate $n = 24$, severe $n = 29$) and 47 newborns who never developed RSV disease as healthy controls included from health centres in the same catchment area. TRECs were measured using DNA extracted from dry blood spots from stored neonatal screening cards, followed by PCR. Student's *T*-test compared patients with controls, ANOVA compared disease severity groups.

Results: During RSV infection patients in the severe disease group had significantly lower ($p = 0.017$) TREC/200 μ L blood compared to the other two disease groups, after correction for lymphocyte count. Newborn TREC levels, were significantly higher in RSV patients compared to controls ($p < 0.0001$). No significant differences in TREC copies at birth were found between disease severities.

Conclusion: During acute RSV infection a lower number of TREC is found in the severe disease group. TREC has potential as an immunological marker for severe RSV infection. Higher neonatal TREC counts indicate that infants later presenting with severe RSV do not have reduced thymic activity at birth and probably no congenital T-cell defect.

Keywords: Respiratory syncytial virus, Thymus, T-cell receptor excision circles, Children, Bronchiolitis

* Correspondence: Kiran.aftab.gul@rr-research.no

¹Department of Pediatric Research, Women and Children's Division, Oslo University Hospital Rikshospitalet, Oslo, Norway

²Department of National Newborn Screening, Women and Children's Division, Oslo University Hospital Rikshospitalet, Oslo, Norway

Full list of author information is available at the end of the article



Background

Respiratory syncytial virus (RSV) infection occurs in annual winter epidemics. Almost all children are exposed before two years of age [1, 2]. Clinical conditions include mild upper respiratory tract infection, bronchiolitis, pneumonia and respiratory failure. 22–31/1000 infants under one year of age [2, 3] are hospitalized and may require supportive treatment including oxygen, fluids, continuous positive airway pressure (CPAP) and in some severe cases mechanical ventilation [1].

Innate immune cells responding to RSV activate naïve T-cells [2], which have a critical role in termination of an acute RSV infection. The thymus has important biological roles in the generation of T-cells from precursor bone marrow derived cells. T-cell receptor excision circles (TRECs) are circular pieces of DNA generated during the rearrangement of variable V, D, and J segments of T-cell receptor (TCR) genes in the thymus [4, 5]. TREC is an accurate measure of thymic function [6] because it arises in the late phase of thymocyte maturation [4, 5]. It can be used to estimate thymic activity in peripheral blood because intrathymic and peripheral TREC values are correlated [7]. In the case of T-cell lymphopenia very low or undetectable TREC levels will be found in peripheral blood, this reflects the lack of T-cells produced by the thymus [4]. TRECs do not replicate during cell division, and are therefore more abundant in naïve T-cells that have recently emigrated from the thymus. Over 70% of rearranged α/β T-cell receptors form a circular DNA TREC [4]. Newborns have high TREC levels that decline with increasing age together with a peripheral T-cell expansion [8].

In the first part of this study we investigated thymus activity in RSV disease using EDTA blood samples collected during a prospective study of RSV bronchiolitis. The results indicated low TREC counts in the severe disease group. Furthermore, to determine if these patients had low thymus activity (TRECs) already from birth, we quantified TRECs in dried blood spot (DBS) of newborn screening (NBS) filter cards and compared them to controls. Other thymic markers such as TCR delta chain (TCRD) and the amount of regulatory T cells (Tregs) are also well correlated with thymic capacity [9]; we decided to use TREC because the method has been established in our laboratory as a screening tool for patients with severe combined immunodeficiency.

The aim of this study was to investigate thymus activity in patients with RSV infection, both at birth in those who later developed RSV disease and during disease, and the impact of thymus activity on disease severity.

Methods

During the RSV season in Akershus and North Oslo, Norway, from January – March 2011, infants < 12 months

of age with respiratory tract infection examined at the paediatric emergency unit, Akershus University Hospital were considered for inclusion in a study of nasal mucosa miRNA expression [10]. One hundred and thirteen patients and 102 controls were recruited. Clinical data and blood samples from patients were collected for later analysis. The controls were recruited from the local health centres.

In our prospective study EDTA blood available in 47 of the included patients were used. The patients were grouped into mild, moderate and severe disease based on clinical data. On inclusion, patients were assessed by the treating paediatrician for respiratory distress using the validated Respiratory Distress Assessment Instrument (RDAI) [11]. The RDAI assesses retractions (max 9 points), wheeze (max 8 points) and changes in respiratory rate. A modified RDAI (m-RDAI) was developed to permit a single observation of respiratory rate and is described further in Table 1 [10]. Children receiving oxygen or fluid supplement, continuous positive airways pressure (CPAP) or mechanical ventilation was classified with severe disease. Children not admitted were classified with mild disease. Children admitted but who did not receive oxygen, fluids, CPAP or mechanical ventilation were classified with moderate disease if they had an m-RDAI 9–25, and with mild disease if they had an m-RDAI 0–8. Clinical characteristics and treatments given are provided in Table 2.

To investigate TREC numbers at birth dried blood on filter cards taken as part of the national neonatal screening program was used. All 113 RSV-positive patients and 102 control infants were invited to participate in a case-control study, 85 patients and 47 controls consented. Letters of invitation, consent forms and a questionnaire were sent autumn 2014. Controls were asked about chronic diseases, if they had ever been admitted to hospital or been positive for RSV. Patients and controls with congenital heart disease, chronic lung disease including treated asthma or bronchopulmonary dysplasia, neurological disease, Down's syndrome, hypotonia, failure to thrive, born <34 weeks gestation, or with other specific conditions associated with more severe disease were excluded.

Sample collection and virus detection

Infants with suspected RSV infection underwent deep nasal aspiration. Two ml viral transport medium was then suctioned through the suction tube into the sample collection tubes. A rapid antigen test (Abbott TestPack RSV, Abbott laboratories) [12] and/ or multiplex quantitative PCR (qPCR) (in-house test) at the Department of Microbiology, Akershus University Hospital confirmed RSV infection. Blood was collected in 2 ml EDTA tubes on inclusion and stored at -80 °C. Automated differential

Table 1 Modified respiratory distress assessment Instrument (m-RDAI)

| Points | 0 | 1 | 2 | 3 | 4 |
|--------------------|------|---|----------------------|--|------------------|
| Wheeze | | | | | |
| Expiration | No | End-Expiratory | ½ of inspiration | ¾ of inspiration | Whole expiration |
| Inspiration | No | Partly | Whole inspiration | | |
| Location | None | ≤2 of 4 lung fields | ≥ 3 of 4 lung fields | | |
| Retractions | | | | | |
| Suprasternal | No | Mild | Moderate | Significant | |
| Intercostal | No | Mild | Moderate | Significant | |
| Subcostal | No | Mild | Moderate | Significant | |
| Respiratory rate | | Upper limit for normal respiratory rate | | Points | |
| Age < 1 month | | 50/ min | | 1 point for each increment of 5 breaths/minute above normal, max. 8 points | |
| Age 1–5 months | | 40/ min | | | |
| Age 6–11 months | | 30/ min | | | |

Maximum score for wheeze - 8 points; for retractions - 9 points; for respiratory rate - 8 points. Thus RR, retractions and wheeze are equally weighted. Maximum m-RDAI score is 25 points. Adapted from [11]. Age-associated limits for respiratory rate (RR) were set according to the literature and clinical experience. Example - a 3-month old child with a respiratory rate of 62 receives 5 points for Respiratory rate (62-40 = 22; 22/5 = 4.4; round up to 5)

white blood cell count was performed. Stored blood samples on filter cards from the National NBS Diagnostic Biobank (Oslo University Hospital, Norway) were collected 3 days after birth and stored between -20° and -25 °C. Previous reports demonstrate no significant difference in TREC values between new and old filter cards [13, 14].

DNA-extraction

Genomic DNA from 200 µl blood was extracted in 100 µl elution solution using the Blood DNA kit (Omega-Biotek, USA) protocol. DNA concentration was measured using Nanodrop (Spectrophotometer ND-1000, USA). A 3.2 mm punch from neonatal screening filter cards was washed with 150 µl DNA Elution solution Qiagen (S2) at 60 °C whilst shaking at 1000 rpm for 10 min in a thermo shaker (TS-100 Biosan, EU) followed by DNA elution in 100 µl S2 at 99.5 °C with continuous shaking at 1000 rpm for 30 min.

Quantitative PCR

DNA extracts were analysed by qPCR on an ABI Via7 (Applied Biosystems), as previously described [15]. The DNA extract from dried blood spots (DBS) was investigated using the same protocol, modified by using quanta perfecta mastermix (QuantaBio, Beverly, MA).

A TREC plasmid, generated by Douek [4], was provided by the Medical College of Wisconsin, and used to construct the standard curve ranging from 40 000 copies to 10 copies with TREC plasmid concentrations diluted in dilution solution (Qiagen Generation solution 2 containing tRNA 100 ng/µl). Nanodrop (Spectrophotometer ND-1000) was used to measure TREC plasmid concentration. We used β-actin as housekeeping gene to assure

adequate DNA extraction. All analyzed qPCR assays had similar slopes and R^2 values > 0.99.

Statistical analysis

IBM SPSS version 22.0 was used for statistical analyses. Clinical characteristics were compared between mild, moderate and severe disease groups using One-way ANOVA, Kruskal-Wallis or Chi-squared tests as appropriate. Length of hospital stay and measures of respiratory distress were compared between moderate and severe disease groups using Mann-Whitney or Fisher's exact tests. One-way ANOVA was used to compare TREC copies and lymphocyte counts between severity groups during RSV disease, with post-hoc analysis using least significant difference (LSD). Univariate linear regression analysis was used to compare TREC copies with lymphocyte counts. Analysis of covariance (ANCOVA) is a general linear model that allows comparison of a continuous variable between groups whilst adjusting for other continuous variables. ANCOVA was used to adjust for effects of lymphocyte count when comparing TREC counts between disease severity groups. Estimated marginal means and 95% confidence interval for TREC copies by group were extracted from the ANCOVA.

TREC copies at birth were not normally distributed and were log transformed prior to statistical analysis. Student's *T*-test was used to compare controls and RSV positive patients. One-way ANOVA was used to compare TREC copies between controls and the three severity groups with post-hoc testing using Dunnett's test, in which each severity group was compared to the control group.

Table 2 Clinical characteristics of RSV-positive infants, categorised by disease severity

| | Mild | | Moderate | | Severe | | Sig. |
|--|------|-------------|----------|-----------|--------|-----------|----------------------------------|
| Total number of patients | 37 | | 25 | | 40 | | |
| TREC during RSV infection, number of patients | 13 | | 10 | | 24 | | |
| TREC in neonatal screening cards, number of patients | 32 | | 24 | | 29 | | |
| Age when RSV diseased - months, median (IQR) | 3 | (1–6) | 3 | (1–5.5) | 2 | (1–4) | $p = 0.4^a$ |
| Male gender, number (%) | 14 | (38%) | 14 | (56%) | 17 | (43%) | $p = 0.4^b$ |
| Weight - grams, mean (SD) | 6522 | (2277) | 6748 | (1935) | 5974 | (2065) | $p = 0.4^c$ |
| Duration of symptoms at admission - days, median (IQR) | 4 | (3–5.25) | 4 | (3.5–5) | 4 | (3–5) | $p = 0.9^a$ |
| Admission, number (%) | 20 | (54%) | 25 | (100%) | 40 | (100%) | |
| Length of stay, median (IQR) | 1 | (0–1) | 1 | (1–3) | 4 | (2.5–5.5) | $p < 0.0001^d$ |
| Length of stay > 3 days, number (%) | 1 | (3%) | 3 | (12%) | 24 | (62%) | $p < 0.0001^e$ |
| Respiratory distress | | | | | | | |
| SpO ₂ - % on admission, mean (SD) | 97.4 | (2.6) | 97.9 | (2.3) | 94.7 | (4.5) | $p < 0.0001^c$ |
| Respiratory rate /min on admission, mean (SD) | 49 | (12) | 58 | (12) | 57 | (10) | $p = 0.002^c$ |
| Respiratory rate score (max. 8), median (IQR) | 2 | (0.75–4.25) | 4 | (2.5–6) | 4 | (2–6) | $p = 0.007^a$ $p = 0.4^d$ |
| Retraction score (max. 9), median (IQR) | 1 | (0–2) | 4 | (2.25–6) | 2 | (1–4) | $p < 0.0001^a$ $p = 0.003^d$ |
| Wheeze score (max. 8), median (IQR) | 0 | (0–3) | 5 | (4–6) | 2 | (0–4) | $p < 0.0001^a$ $p = 0.0002^d$ |
| m-RDAI, median (IQR) | 6 | (2–8) | 13 | (10.5–16) | 8 | (6–11) | $p < 0.0001^a$ $p < 0.0001^d$ |
| Treatments | | | | | | | |
| Fluid supplement, number (%) | | | | | 16 | (40%) | |
| Intravenous fluids, number (%) | | | | | 4 | (10%) | |
| Nasogastric fluid, number (%) | | | | | 14 | (35%) | |
| Oxygen supplement, number (%) | | | | | 35 | (88%) | |
| CPAP, number (%) | | | | | 4 | (10%) | |
| Respirator, number (%) | | | | | 0 | (0%) | |

Of 113 patients available for the study, 92 were included. Fortyseven had TREC analysed during acute RSV infection, 85 had TREC analysed in neonatal screening cards. Values presented and statistical tests are performed using the total number of RSV positive children included in this study. Analyses show similar results when including only infants studied in the analysis of TREC during RSV infection, or only infants studied in the analysis of neonatal TREC (details not presented). There were no significant differences in age, weight, gender or duration of symptoms between disease severity groups. The severe disease group had a lower SpO₂ on admission, but had less respiratory distress than the moderate group, as measured by the m-RDAI. The retraction and wheeze scores in particular contributed to this difference. Length of hospital stay increased with increasing severity. The most common treatment for children with severe disease was oxygen supplementation. Only four children required admission to intensive care for CPAP. None were ventilated

^aKruskal-Wallis test

^bChi-Square test

^cOne-way ANOVA

^dMann-Whitney test, comparing moderate and severe disease subgroups

^eFisher's exact test, comparing moderate and severe disease subgroups

Results

TREC in RSV positive children during acute illness

EDTA blood was available for 47 patients and lymphocyte counts for 64. Significant correlation between TREC copies and disease severity was found ($p = 0.007$). Mean TREC copies in mild disease group was 29×10^3 TREC/200 μ l (95% CI 15–43 $\times 10^3$ TREC/200 μ l), moderate group 40×10^3 TREC/200 μ l (95% CI 24–57 $\times 10^3$ TREC/200 μ l), and severe disease group 22×10^3 TREC/200 μ l

(95% CI 10–33 $\times 10^3$ TREC/200 μ l). Reduced TREC copies were identified in the severe disease group compared to mild and moderate ($p = 0.038$ and $p = 0.003$, respectively). Lymphocyte counts showed a similar pattern, but was not statistically significant ($p = 0.21$). Since TREC copies were strongly correlated to lymphocyte count ($p = 0.00001$; $R^2 = 0.371$), we wished to exclude lymphocyte count as a confounder. On analysis using ANCOVA, disease severity maintained a significant effect

on TREC copies ($F = 4.6$; $p = 0.017$; partial $\text{Et}^2 = 0.189$), as did lymphocyte count ($F = 19$; $p = 0.00009$; partial $\text{Et}^2 = 0.328$) and the corrected model $F = 12.5$; $p = 0.000007$; Partial $\text{Et}^2 = 0.49$. Post-hoc testing in this adjusted model confirmed reduced TREC in the severe disease group compared to mild and moderate groups ($p = 0.07$ and 0.007 , respectively). Results are shown in Fig. 1.

TREC in neonatal DBS filter cards from patients and controls

Eightyfive/113 (75%) RSV-positive (mild $n = 32$, moderate $n = 24$, severe $n = 29$) and 60/102 (59%) controls consented to the neonatal filter card study. Fortyseven (78%) controls were eligible for inclusion. There were significantly higher TREC copies in neonatal filtercards of RSV positive patients ($p < 0.0001$, Student's T -test); mean TREC copies 551 TREC/ μl in RSV positive patients (95% CI 493–609 TREC/ μl) compared to 388 TREC/ μl in controls (95% CI 329–426 TREC/ μl). There was no significant

difference between disease subgroups. Significantly higher TREC copies were found when those who later developed mild and severe disease subgroups were compared to controls ($p < 0.0001$, $p = 0.012$, respectively). Results are shown in Fig. 2.

Discussion

We found that children assessed at the hospital emergency ward for RSV infection have lower TREC counts in whole blood in cases with severe disease compared to mild and moderate disease. RSV positive patients had higher neonatal TRECs compared to controls, but there were no differences between disease severity groups at birth.

Differentiation between severe disease and moderate disease was based on treatments given, which are objective end-points. Differentiation between mild and moderate groups was based on an assessment of respiratory distress on admission. Follow up assessment of respiratory distress during admission may have identified patients in the mild





Fig. 1 TREC and lymphocyte counts in infants with active Respiratory syncytial virus disease, by disease severity. Note: Panels **a** and **b**: T-cell receptor excision circle (TREC) copy numbers and lymphocyte counts in peripheral blood according to disease severity. TREC counts are significantly lower in the severe disease group. Lymphocyte counts show a similar pattern, but this is not significant. Plots show mean counts with 95% confidence intervals. Panel **c**: Scatterplot of TREC vs. lymphocyte counts. There is a strong positive correlation between TREC counts and lymphocyte counts ($p = 0.00001$; $R^2 = 0.371$). Panel **d**: Because TREC counts were strongly correlated to lymphocyte counts, and lymphocyte counts showed a similar pattern to TRECs between groups, TREC counts were adjusted for lymphocytes using ANCOVA. Estimated marginal means with 95% confidence intervals for TREC copies are presented. The difference in TREC count between disease severities remains significant. Post-hoc testing identified the severe disease group as having a lower adjusted TREC count than mild and moderate disease subgroups ($p = 0.07$ and $p = 0.007$, respectively). There was no difference between mild and moderate groups



group who qualified for the moderate group. There may also be some overlap between mild disease cases and controls. Controls did not present to paediatric units in our region and the general practitioner of these patients did not send a nasopharyngeal aspirate for RSV detection. However, almost all children are exposed to RSV by age two years and it is therefore highly likely that controls have also been exposed to RSV, but had a mild course of infection [2].

RSV positive children during acute illness

We found lower TREC counts in the whole blood of severe RSV patients, but no significant difference in lymphocyte levels. The literature suggests several mechanisms that might explain reduced TREC counts in severe RSV disease: i) reduced thymic activity, ii) increased lymphocyte apoptosis, or iii) redistribution of lymphocytes to other tissues than peripheral blood. Glucocorticoid-

mediated thymic suppression is associated with stress [16], which is more likely in severe disease. This concurs with previous studies reporting decreased lymphocytes associated with severe stress in septic patients and after cardiac bypass [17]. Previously published studies report a reduction in absolute lymphocyte counts in children with acute RSV, with most pronounced effects in children who require intensive care [17]. Depletion of T-lymphocyte activity has been associated with mechanical ventilation [18] and a longer duration of oxygen supplementation in infants with RSV infection [19]. The symptoms and signs of RSV disease in our patients varied. Only a few received intensive care and none were ventilated. This patient cohort is therefore representative for the great majority of RSV positive patients presenting to hospital, but not for those with the most severe forms of RSV infection. This may explain the discrepancy between our study and previous reports. A study of peripheral blood during RSV infection did not find differences in T-lymphocyte cytokines between disease severity groups, but lymphocytes had a reduced lymphoproliferative response on stimulation with phytohaemagglutinin [20].

Increased lymphocyte apoptosis in patients with acute RSV infection was suggested in a study by Roe et al. [21] in which expression of the apoptosis-promoting proteins Fas and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor on CD4⁺ and CD8⁺ T-cells during the acute phase was upregulated compared to recovery phase samples [17]. Finally, redistribution of peripheral blood lymphocytes to the lungs during RSV disease was reported [22], and was most pronounced in severe disease. This is in contrast to our study, as lymphocyte levels were not significantly lower in severe disease, which may reflect the paucity of patients requiring mechanical ventilation.

Our study took advantage of samples already available in a biobank and therefore had several limitations. It would have been useful to measure other markers of lymphocyte activity, and to differentiate between T-lymphocytes, including T-lymphocyte subtypes, and B-lymphocytes. In our study, blood samples were taken on presentation to hospital, in many cases before the need for oxygen supplementation arose (median SpO₂ 94.7% on admission in the severe disease group, see Table 1), and compared to other studies no patients were mechanically ventilated. TREC might therefore be a more sensitive biomarker for disease severity than cytokines, lymphocyte levels or lymphocyte responses. Further studies could investigate TREC's potential to guide clinical decisions.

Neonatal DBS filter cards from patients and controls

Evaluation of the immune system prior to infection is particularly interesting, because it may uncover deficiencies that predispose infants to more severe disease.

In this study we find higher neonatal TREC counts at birth in patients compared to controls. RSV disease severity is thus not associated with reduced thymic activity at birth, and patients are unlikely to carry a congenital T-cell defect. Increased TREC numbers may nevertheless reflect an immature adaptive immune system.

TREC counts increase on production of TREC positive naive T-cells by the thymus, and decrease on cell death or on dilution during peripheral division of the T-cell pool [4, 23]. High TREC levels in our patients may result from a normal continuous thymic output and reduced peripheral expansion of the naive T-cell pool [17]. We have previously published in a prospective study evidence that IL7R gene is down regulated in cord blood of patients later diagnosed with RSV infection [24]. Our present findings concur with these results. Cytokines, most importantly IL-7, has a crucial role in proliferation and survival of the naive T-cell pool [17]. Reduced IL-7R expression causes lower proliferation of naive T-cells. The overall effect may therefore be that neonates who later present to hospital with RSV have a greater proportion of naive lymphocytes in their peripheral blood compared to other neonates, and reduced peripheral expansion of lymphocytes carrying RSV-antigen receptors. We propose that reduced peripheral expansion or prolonged naive T-cell survival may delay the adaptive immune response, allowing prolonged viral replication and a greater innate inflammatory response, both factors associated with increased disease severity [25–28].

Conclusion

In acute RSV disease, we found lower TREC counts in infants with severe disease, suggesting that it has potential as a biomarker for severe disease. We found higher TREC numbers in neonatal DBS filter cards in patients than in controls, suggesting that patients later diagnosed with RSV do not have reduced thymus activity from birth and probably no congenital T-cell defect.

Abbreviations

ANCOVA: Analysis of covariance; CPAP: Continuous positive airway pressure; DBS: Dried blood spots; DC: Dendritic cells; EDTA: Ethylenediaminetetraacetic acid; LSD: Least significant difference; NBS: Newborn screening; qPCR: quantitative PCR; RDAI: Respiratory distress assessment instrument; RR: Respiratory rate; RSV: Respiratory syncytial virus; TCR: T-cell receptor; TRECs: T-cell receptor excision circles

Acknowledgements

We are thankful to Rolf D Pettersen Department of National Newborn Screening Oslo University Hospital for providing us dried blood on newborn screening filtercards.

Funding

This work was supported by Oslo University Hospital Norway and Akershus University Hospital.

Availability of data and materials

The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.

Authors' contributions

All authors have seen and approved the content of the final manuscript. All authors contributed to study conception and design, interpretation of results and manuscript preparation. Author KGA was responsible for laboratory procedures and prepared the first version of the manuscript. Author CSI was responsible for collection of clinical data and specimens and statistical analysis.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

The Regional Committee for Research Ethics (2012/806b) and the hospital's Data Protection Officer approved the study. Written, informed consent was obtained from the guardians of all infants prior to inclusion in 2011, and additional consent obtained in 2014 prior to analysis of dried blood from NBS cards.

Author details

¹Department of Pediatric Research, Women and Children's Division, Oslo University Hospital Rikshospitalet, Oslo, Norway. ²Department of National Newborn Screening, Women and Children's Division, Oslo University Hospital Rikshospitalet, Oslo, Norway. ³Department of Pediatric and Adolescent Medicine, Akershus University Hospital, Lørenskog, Norway. ⁴Department of Clinical Molecular Biology and Laboratory Sciences (EpiGen), University of Oslo, Akershus University Hospital, Lørenskog, Norway. ⁵Institute of Clinical Medicine, University of Oslo, Oslo, Norway. ⁶Clinic of Pediatric and Adolescent Medicine, Women and Children's Division, Oslo University Hospital Rikshospitalet, Oslo, Norway.

Received: 11 July 2016 Accepted: 21 December 2016

Published online: 05 January 2017

References

1. Law BJ, Carbonell-Estrany X, Simoes EA. An update on respiratory syncytial virus epidemiology: a developed country perspective. *Respir Med.* 2002;96 Suppl B:S1–7.
2. Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. *Am J Dis Child.* 1986;140(6):543–6.
3. Fjærli HO, Farstad T, Bratlid D. Hospitalisations for respiratory syncytial virus bronchiolitis in Akershus, Norway, 1993–2000: a population-based retrospective study. *BMC Pediatr.* 2004;4(1):25.
4. Douek DC, McFarland RD, Keiser PH, Gage EA, Massey JM, Haynes BF, Polis MA, Haase AT, Feinberg MB, Sullivan JL, et al. Changes in thymic function with age and during the treatment of HIV infection. *Nature.* 1998; 396(6712):690–5.
5. Hazenberg MD, Verschuren MC, Hamann D, Miedema F, van Dongen JJ. T cell receptor excision circles as markers for recent thymic emigrants: basic aspects, technical approach, and guidelines for interpretation. *J Mol Med (Berl).* 2001;79(11):631–40.
6. Arellano MV, Ordonez A, Ruiz-Mateos E, Leal-Noval SR, Molina-Pinelo S, Hernandez A, Vallejo A, Hinojosa R, Leal M. Thymic function-related markers within the thymus and peripheral blood: Are they comparable? *J Clin Immunol.* 2006;26(1):96–100.
7. Dion ML, Sekaly RP, Cheynier R. Estimating thymic function through quantification of T-cell receptor excision circles. *Methods Mol Biol.* 2007; 380:197–213.
8. Puck JM. The case for newborn screening for severe combined immunodeficiency and related disorders. *Ann N Y Acad Sci.* 2011;1246:108–17.
9. Machnes-Maayan D1 LA, Katz U, Mishali D, Vardi A, Simon AJ, Somech R. Insight into normal thymic activity by assessment of peripheral blood samples. *Immunol Res.* 2015;61(3):198–205.

10. Inchley CS, Sonerud T, Fjaerli HO, Nakstad B. Nasal mucosal microRNA expression in children with respiratory syncytial virus infection. *BMC Infect Dis.* 2015;15:150.
11. Lowell DI, Lister G, Von KH, McCarthy P. Wheezing in infants: the response to epinephrine. *Pediatrics.* 1987;79(6):939–45.
12. Olsen MA, Shuck KM, Sambol AR. Evaluation of Abbott TestPack RSV for the diagnosis of respiratory syncytial virus infections. *Diagn Microbiol Infect Dis.* 1993;16(2):105–9.
13. Cruickshank MN, Pitt J, Craig JM. Going back to the future with Guthrie-powered epigenome-wide association studies. *Genome Med.* 2012;4(10):83.
14. Lingman Framme J, Borte S, von Döbeln U, Hammarström L, Oskarsdóttir S. Retrospective analysis of TREC based newborn screening results and clinical phenotypes in infants with the 22q11 deletion syndrome. *J Clin Immunol.* 2014;34(4):514–9.
15. Gul KA, Overland T, Osnes L, Baumbusch LO, Pettersen RD, Lima K, Abrahamsen TG. Neonatal Levels of T-cell Receptor Excision Circles (TREC) in Patients with 22q11.2 Deletion Syndrome and Later Disease Features. *J Clin Immunol.* 2015;35(4):408–15.
16. Park JH, Yu Q, Erman B, Appelbaum JS, Montoya-Durango D, Grimes HL, Singer A. Suppression of IL7Ralpha transcription by IL-7 and other pro-survival cytokines: a novel mechanism for maximizing IL-7-dependent T cell survival. *Immunity.* 2004;21(2):289–302.
17. Mahajan VS, Leskov IB, Chen JZ. Homeostasis of T cell diversity. *Cell Mol Immunol.* 2005;2(1):1–10.
18. Bont L, Heijnen CJ, Kavelaars A, van Aalderen WM, Brus F, Draaisma JM, Pekelharing-Berghuis M, van Diemen-Steenvoorde RA, Kimpen JL. Local interferon-gamma levels during respiratory syncytial virus lower respiratory tract infection are associated with disease severity. *J Infect Dis.* 2001;184(3):355–8.
19. Garcia C, Soriano-Fallas A, Lozano J, Leos N, Gomez AM, Ramilo O, Mejias A. Decreased innate immune cytokine responses correlate with disease severity in children with respiratory syncytial virus and human rhinovirus bronchiolitis. *Pediatr Infect Dis J.* 2012;31(1):86–9.
20. Bont L, van Vught AJ, Kimpen JL. Prophylaxis against respiratory syncytial virus in premature infants. *Lancet.* 1999;354(9183):1003–4.
21. Roe MF, Bloxham DM, White DK, Ross-Russell RI, Tasker RT, O'Donnell DR. Lymphocyte apoptosis in acute respiratory syncytial virus bronchiolitis. *Clin Exp Immunol.* 2004;137(1):139–45.
22. De Weerd W, Twilhaar WN, Kimpen JL. T cell subset analysis in peripheral blood of children with RSV bronchiolitis. *Scand J Infect Dis.* 1998;30(1):77–80.
23. Hazenberg MD, Otto SA, de Pauw ES, Roelofs H, Fibbe WE, Hamann D, Miedema F. T-cell receptor excision circle and T-cell dynamics after allogeneic stem cell transplantation are related to clinical events. *Blood.* 2002;99(9):3449–53.
24. Inchley CS, Osterholt HC, Sonerud T, Fjaerli HO, Nakstad B. Downregulation of IL7R, CCR7, and TLR4 in the cord blood of children with respiratory syncytial virus disease. *J Infect Dis.* 2013;208(9):1431–5.
25. Houben ML, Coenjaerts FE, Rossen JW, Belderbos ME, Hofland RW, Kimpen JL, Bont L. Disease severity and viral load are correlated in infants with primary respiratory syncytial virus infection in the community. *J Med Virol.* 2010;82(7):1266–71.
26. El Saleeby CM, Bush AJ, Harrison LM, Aitken JA, Devincenzo JP. Respiratory syncytial virus load, viral dynamics, and disease severity in previously healthy naturally infected children. *J Infect Dis.* 2011;204(7):996–1002.
27. Mella C, Suarez-Arrabal MC, Lopez S, Stephens J, Fernandez S, Hall MW, Ramilo O, Mejias A. Innate immune dysfunction is associated with enhanced disease severity in infants with severe respiratory syncytial virus bronchiolitis. *J Infect Dis.* 2013;207(4):564–73.
28. Smyth RL, Mobbs KJ, O'Hea U, Ashby D, Hart CA. Respiratory syncytial virus bronchiolitis: disease severity, interleukin-8, and virus genotype. *Pediatr Pulmonol.* 2002;33(5):339–46.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at
www.biomedcentral.com/submit

